MediPharm Labs Sets Date to Report Third Quarter 2024 Financial Results
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), a pharmaceutical company specializing in precision-based cannabinoids, announced it will release its third quarter financial results on November 14, 2024, before the market opens. The results will cover the three and nine months ended September 30, 2024.
An updated company presentation with select highlights from the period will be available on MediPharm's website following the release. Notably, the company will not host a quarterly earnings call.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), un'azienda farmaceutica specializzata in cannabinoidi di precisione, ha annunciato che rilascerà i risultati finanziari del terzo trimestre il 14 novembre 2024, prima dell'apertura del mercato. I risultati copriranno i tre e nove mesi conclusi il 30 settembre 2024.
Una presentazione aziendale aggiornata con evidenze selezionate del periodo sarà disponibile sul sito web di MediPharm dopo il rilascio. È importante notare che l'azienda non terrà una teleconferenza sui risultati trimestrali.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), una empresa farmacéutica especializada en cannabinoides basados en la precisión, anunció que publicará sus resultados financieros del tercer trimestre el 14 de noviembre de 2024, antes de la apertura del mercado. Los resultados cubrirán los tres y nueve meses que finalizaron el 30 de septiembre de 2024.
Una presentación actualizada de la empresa con aspectos destacados seleccionados del período estará disponible en el sitio web de MediPharm tras la publicación. Cabe destacar que la empresa no realizará una conferencia telefónica sobre los resultados trimestrales.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), 정밀 기반의 칸나비노이드에 전문화된 제약 회사가 2024년 11월 14일에 시장 개장 전에 제3분기 재무 결과를 발표할 것이라고 발표했습니다. 이 결과는 2024년 9월 30일 기준으로 종료된 3개월 및 9개월을 포함합니다.
발표 후, 특별히 선정된 기간의 하이라이트가 포함된 업데이트된 회사 프레젠테이션이 MediPharm 웹사이트에 제공될 것입니다. 특히, 회사는 분기 실적 발표 전화 회의를 진행하지 않을 것입니다.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), une entreprise pharmaceutique spécialisée dans les cannabinoïdes basés sur la précision, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre le 14 novembre 2024, avant l'ouverture du marché. Les résultats couvriront les trois et neuf mois se terminant le 30 septembre 2024.
Une présentation mise à jour de l'entreprise, contenant les points saillants sélectionnés de la période, sera disponible sur le site Web de MediPharm après la publication. Il est à noter que l'entreprise ne tiendra pas de conférence téléphonique sur les résultats trimestriels.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), ein Pharmaunternehmen, das sich auf präzisionsbasierte Cannabinoide spezialisiert hat, gab bekannt, dass es seine finanziellen Ergebnisse für das dritte Quartal am 14. November 2024, vor der Markteröffnung veröffentlichen wird. Die Ergebnisse beziehen sich auf die drei und neun Monate, die am 30. September 2024 endeten.
Eine aktualisierte Unternehmenspräsentation mit ausgewählten Highlights aus dem Zeitraum wird nach der Veröffentlichung auf der Website von MediPharm verfügbar sein. Auffällig ist, dass das Unternehmen kein vierteljährliches Gewinnaufruf veranstalten wird.
- Scheduled release of Q3 financial results on November 14, 2024.
- Updated company presentation available post-release.
- No quarterly earnings call hosted by management.
An updated company presentation including select highlights from the period ended September 30, 2024 will be available on MediPharm's website following the earnings release, this in lieu of a quarterly earnings call hosted by management.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in
In 2023, MediPharm acquired VIVO Cannabis Inc. which expanded MediPharm's reach to medical patients in
The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Website: www.medipharmlabs.com
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding the release of MediPharm's financial results and the future of MediPharm's foreign drug manufacturing site registration. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
View original content to download multimedia:https://www.prnewswire.com/news-releases/medipharm-labs-sets-date-to-report-third-quarter-2024-financial-results-302300680.html
SOURCE MediPharm Labs Corp.
FAQ
When will MediPharm Labs release its Q3 2024 financial results?
Will MediPharm Labs host a quarterly earnings call for Q3 2024?
Where can I find the updated company presentation for MediPharm Labs' Q3 2024 results?
